Pfizer Inc. $PFE Shares Acquired by Ingalls & Snyder LLC

Ingalls & Snyder LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 7.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 755,313 shares of the biopharmaceutical company’s stock after acquiring an additional 51,993 shares during the quarter. Ingalls & Snyder LLC’s holdings in Pfizer were worth $18,309,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the first quarter valued at approximately $27,000. Curio Wealth LLC raised its stake in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd acquired a new stake in Pfizer during the first quarter valued at approximately $28,000. North Capital Inc. acquired a new stake in Pfizer during the first quarter valued at approximately $28,000. Finally, Harbor Asset Planning Inc. acquired a new stake in Pfizer during the second quarter valued at approximately $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on PFE. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley lowered their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Stock Performance

PFE opened at $24.79 on Friday. The company has a market capitalization of $140.92 billion, a price-to-earnings ratio of 13.18, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.17. The business has a 50 day moving average price of $24.87 and a two-hundred day moving average price of $24.18.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.